Olejniczak K - Search Results

1

Approaches for assessing risks to sensitive populations: lessons learned from evaluating risks in the pediatric population.

Hines RN, Sargent D, Autrup H, Birnbaum LS, Brent RL, Doerrer NG, Cohen Hubal EA, Juberg DR, Laurent C, Luebke R, Olejniczak K, Portier CJ, Slikker W. Hines RN, et al. Among authors: olejniczak k. Toxicol Sci. 2010 Jan;113(1):4-26. doi: 10.1093/toxsci/kfp217. Epub 2009 Sep 21. Toxicol Sci. 2010. PMID: 19770482 Free PMC article. Review.

2

Children as a sensitive subgroup and their role in regulatory toxicology: DGPT workshop report.

Schwenk M, Gundert-Remy U, Heinemeyer G, Olejniczak K, Stahlmann R, Kaufmann W, Bolt HM, Greim H, von Keutz E, Gelbke HP; DGPT. Schwenk M, et al. Among authors: olejniczak k. Arch Toxicol. 2003 Jan;77(1):2-6. doi: 10.1007/s00204-002-0416-9. Epub 2002 Nov 22. Arch Toxicol. 2003. PMID: 12491033 Review.

3

Replacement of in vivo acute oral toxicity studies by in vitro cytotoxicity methods: opportunities, limits and regulatory status.

Ukelis U, Kramer PJ, Olejniczak K, Mueller SO. Ukelis U, et al. Among authors: olejniczak k. Regul Toxicol Pharmacol. 2008 Jun;51(1):108-18. doi: 10.1016/j.yrtph.2008.02.002. Epub 2008 Feb 21. Regul Toxicol Pharmacol. 2008. PMID: 18362045

4

Indirect human exposure to pharmaceuticals via drinking water.

Webb S, Ternes T, Gibert M, Olejniczak K. Webb S, et al. Among authors: olejniczak k. Toxicol Lett. 2003 May 15;142(3):157-67. doi: 10.1016/s0378-4274(03)00071-7. Toxicol Lett. 2003. PMID: 12691710

5

The need for juvenile animal studies--a critical review.

Soellner L, Olejniczak K. Soellner L, et al. Among authors: olejniczak k. Regul Toxicol Pharmacol. 2013 Feb;65(1):87-99. doi: 10.1016/j.yrtph.2012.10.010. Epub 2012 Oct 27. Regul Toxicol Pharmacol. 2013. PMID: 23108189 Review.

6

Challenges and lessons learned since implementation of the safety pharmacology guidance ICH S7A.

Valentin JP, Bass AS, Atrakchi A, Olejniczak K, Kannosuke F. Valentin JP, et al. Among authors: olejniczak k. J Pharmacol Toxicol Methods. 2005 Jul-Aug;52(1):22-9. doi: 10.1016/j.vascn.2005.04.009. J Pharmacol Toxicol Methods. 2005. PMID: 15961324 Review.

7

Evaluation of carcinogenicity studies of medicinal products for human use authorised via the European centralised procedure (1995-2009).

Friedrich A, Olejniczak K. Friedrich A, et al. Among authors: olejniczak k. Regul Toxicol Pharmacol. 2011 Jul;60(2):225-48. doi: 10.1016/j.yrtph.2011.04.001. Epub 2011 Apr 13. Regul Toxicol Pharmacol. 2011. PMID: 21513764

8

Critical evaluation of the use of dogs in biomedical research and testing in Europe.

Hasiwa N, Bailey J, Clausing P, Daneshian M, Eileraas M, Farkas S, Gyertyán I, Hubrecht R, Kobel W, Krummenacher G, Leist M, Lohi H, Miklósi A, Ohl F, Olejniczak K, Schmitt G, Sinnett-Smith P, Smith D, Wagner K, Yager JD, Zurlo J, Hartung T. Hasiwa N, et al. Among authors: olejniczak k. ALTEX. 2011;28(4):326-40. doi: 10.14573/altex.2011.4.326. ALTEX. 2011. PMID: 22130483 Free article.

9

Biomarkers in the drug development process: report from workshop discussions.

van Gool AJ, Spindler P, Harpur E, Bounous D, Olejniczak K, van de Klundert FA, Haenen B. van Gool AJ, et al. Among authors: olejniczak k. Regul Toxicol Pharmacol. 2008 Nov;52(2):75-6. doi: 10.1016/j.yrtph.2008.05.001. Epub 2008 May 11. Regul Toxicol Pharmacol. 2008. PMID: 18556099 No abstract available.

10

ICH topic: note for guidance on safety pharmacology studies for human pharmaceuticals.

Olejniczak K, Bode G. Olejniczak K, et al. Fundam Clin Pharmacol. 2002 Apr;16(2):79-81. doi: 10.1046/j.1472-8206.2002.00078.x. Fundam Clin Pharmacol. 2002. PMID: 12031060 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

31 results

Search Page

Filters